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The Role of Metals in Carcinogenesis:
Biochemistry and Metabolism
by K. Wetterhahn Jennette*
The oxyanions ofvanadium, chromium, molybdenum, arsenic, and selenium are stable forms
of these elements in high oxidation states which cross cell membranes using the normal
phosphate and/or sulfate transport systems ofthe cell. Once inside the cell, these oxyanions may
act as phosphate and/orsulfate analogs, inhibiting enzymes involved in catalyzing phosphoryl or
sulfuryl transfer reactions. Often the oxyanions serve as alternate enzyme substrates but form
ester products which are hydrolytically unstable compared with the sulfate and phosphate esters
and, therefore, decompose readily in aqueous solution. Arsenite and selenite are capable of
reacting with sulfhydryl groups in proteins. Some cells are able to metabolize redox active
oxyanions to forms of the elements in other stable oxidation states. Specific enzymes may be
involved in the metabolic processes. The metabolites ofthese elements mayform complexes with
small molecules, proteins and nucleic acids which inhibit their ability to function properly.
The divalent ions of beryllium, manganese, cobalt, nickel, cadmium, mercury, and lead are
stable forms of these elements which may mimic essential divalent ions such as magnesium,
calcium, iron, copper, or zinc. These ions may complex small molecules, enzymes, and nucleic
acids in such a way that the normal activity of these species is altered. Free radicals may be
produced in the presence of these metal ions which damage critical cellular molecules.
The biochemistry and metabolism of inorganic
species involved in carcinogenesis encompasses
transport of inorganic species across the cell mem-
brane, enzymatic and chemical transformation of
redox active inorganic species within the cell,
coordination of inorganic species to cellular small
molecules and macromolecules, and inhibition, acti-
vation or change of specificity of cellular enzymes
by inorganic species. Inorganic species may mimic
forms ofessential elements in these processes. The
kinetic and thermodynamic properties ofinorganic
species may be substantially different from those of
essential elements and, therefore, may ultimately
determine the manifestation of cellular damage,
including carcinogenic and cocarcinogenic effects.
Forexample, in orderforan inorganic compound to
be a mutagen it must enter the cell; however, an
inorganic compound may be able to act as a
cocarcinogen without penetration into the cell by
interacting with the cell surface. Once inside the
cell the inorganic species originally transported
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across the cell membrane may be transformed into
a different form by reaction with cellular compo-
nents. The transformation may result in a complex
which is easily excreted, hence deactivated.
Alternatively, the element may be activated and
bind to enzymes and/or nucleic acids, altering their
ability to function properly in the cell. The ultimate
disposition of the element will depend on the
chemical properties of the individual inorganic
species involved.
Oxide Complexes
The early transition elements have a tendency to
exist in high oxidation states as oxy or hydroxy
complexesin aqueous solution (1). The nature ofthe
oxy species depends on concentration and pH. For
example, in neutral aqueous solution at concentra-
tions less than 10M, vanadium (V) exists mainly
as H2VO-; chromium (VI) exists as chromate,
CrO42-; manganese (VII) exists as permanganate,
MnO4;molybdenum(VI)existsasmolybdate, MoO4v.
As the concentration of these species is increased,
themononuclearions aggregate toformpolyanions.
233In addition to the early transition elements, certain
main group elements also tend to exist as oxyanions
(1). At pH 7, phosphorus (V) exists as an equilib-
rium mixture of H2PO04 and HP042; arsenic (V)
exists as an equilibrium mixture of H2As04 and
HAsO42; sulfur (VI) exists as sulfate, S042-; and
selenium (VI) as selenate, SeO42-. All of these
oxyanions have a tetrahedral geometry (Fig. 1).
Other stable oxy-complexes of several of these
elements also exist (1). Vanadium (IV) complexes
are generally five- or six-coordinate and typically
contain the vanadyl ion, V02 . Pyramidal struc-
tures are found for arsenic (LII) which exists in
neutral aqueous solution mainly as protonated ar-
senite, As(OH)3, sulfur (IV) which exists as sulfite,
S%32 and selenium (IV) which exists as selenite,
SeO3 -.
Transport
Since phosphate and sulfate are known to cross
cell membranes by passive transport and mediated
permeation (2), the other oxyanions may use these
transport systems to enter the cells. Arsenate was
foundtoenteryeastcellsbythephosphate transport
system (3). Arsenate was a competitive inhibitor of
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phosphate uptake into 3T3 mouse fibroblast cells,
however, chromate and vanadate showed very
little inhibition of the phosphate transport system
(4). Vanadate crossed the red blood cell membrane
by the anion-exchange system responsible for phos-
phate transport (5). Vanadate uptake was inhibited
by dinitrostilbene disulfonate, a known inhibitor of
anion exchange (5). Vanadate inhibited phosphate
transport into red cells (5).
Chromate was able to cross the membranes and
enter red blood cells (6), Ehrlich ascites carcinoma
cells (7), mastocytoma cells (8) and EL4 ascites
leukemia lymphoblasts (9). The velocity of chro-
mate uptake by human leukocytes was slightly
inhibited by sulfate, tungstate and molybdate;
metavanadate was a competitive inhibitor of chro-
mate transport; arsenite andp-chloromercuribenzene
sulfonate were potent inhibitors ofchromate influx
(10). Transport of molybdate across rat intestinal
membranes was inhibited by sulfate, selenate and
chromate, but not phosphate (11). Sulfate was a
competitive inhibitor of molybdate transport in
everted sacs of rat and ovine small intestines
(12-24). Tungstate, selenate and thiosulfate also
inhibited sulfate transport by rat ileum invitro (12,
13). Sulfate inhibited the absorption of molybdate
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FIGURE 1. Oxyanions and oxo-complexes stable in dilute neutral aqueous solution.
Environmental Health Perspectives 234in isolated chick intestinal loop segments (15).
Active sulfate uptake in the yeast Saccharomyces
cerevisiae was inhibited by chromate, molybdate,
selenate, thiosulfate, sulfite, and tellurite (16). The
activity of the sulfate transport system in the
filamentousfungusPenicilliumnotatumwasstrongly
inhibited by selenate, molybdate, thiosulfate, chro-
mate, and sulfite (17). An active transport system
for molybdate was characterized for the molyb-
denum-requiring nitrogen-fixing bactezium Clostrid-
ium pasteurianum (18). Tungstate and sulfate
were competitive inhibitors ofmolybdate uptake in
these organisms, however, thiosulfate and vana-
date were not inhibitors ofmolybdate uptake (18).
The transport ofsulfate into the bacterium Salmo-
nellatyphimuriumwasstronglyinhibited bysulfite,
chromate, thiosulfate and selenate and was moder-
ately inhibited by molybdate, vanadate, and tung-
state (19).
In summary, oxyanions of chromium, vanadium,
molybdenum, tungsten, arsenic, and selenium, read-
ily permeated the cell membranes of prokaryotes
and eukaryotes. The oxyanions entered the cells by
using the normal active transport systems for
phosphate and sulfate.
Enzyme Interaction
The oxyanions have been shown to affect the
activities of phosphotransferases and phosphohy-
drolases. Human liver and wheat germ acid phos-
phatases were competitively inhibited by arsenate,
vanadate, molybdate, and tungstate (20). Arsenate
(21), vanadate, and vanadyl ion, VO2" (22), were
potent competitive inhibitors of E. coli alkaline
phosphatase; permanganate was an irreversible
inhibitor, whereas chromate and perchlorate were
not inhibitors (23). Molybdate was a potent inhibi-
tor of phosphoprotein phosphatase isolated from
bovine tracheal smooth muscle extract (24). Molyb-
date was a noncompetitive inhibitor of NADP+
2'-nucleotidase from Hevea brasiliensis (25).
Oxovanadium (IV) ion, and complexes of uridine
2'
0
OH2
FIGURE 2. Proposed trigonal bipyramidal transition state in
RNA hydrolysis by ribonuclease A (26).
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with oxovanadium (IV) and vanadate were competi-
tive inhibitors ofribonuclease A (26). The competi-
tive inhibition of enzyme activity was proposed to
bebased onthe ability oftheseionstoformtrigonal
bipyramidal complexes ofthe type shown in Figure
2, which act as transition-state analogs in reactions
involvingphosphate esters (20, 26). The irreversible
inhibition of alkaline phosphatase activity by per-
manganate appeared to be due to oxidation of the
enzyme (16, 20).
Vanadate was found to be a potent inhibitor of
(Na+, K+)ATPases from dog kidney (27, 28), pig
kidney (29), dog brain (28), pig brain (30), eel
electroplax (28), red blood cells (5), and squid axons
(31), dynein ATPases from sea urchin sperm (30,
32) and Tetrahymena pyriformis (32), myosin
ATPases from human platelets (32), and rabbit
muscle (32, 33), and (Ca)ATPases from red blood
cells (32) and squid axons (35). Vanadate did not
inhibit rabbit muscle sarcoplasmic reticulum
(Ca)ATPase orbeefheartmitochondrial F1 ATPase
(28).
Vanadate formed a stable stoichiometric ternary
complex with ADP and myosin ATPase [Eq. (1)]
and it was proposed that the vanadate was coordi-
nated to nucleophiles in the active site of the
enzyme (33). Vanadate interacted stronglywith the
lowaffinityATPsiteofdogkidney(Na+,K+)ATPase
[Eq. (2)] and increased the affinity of the enzyme
forMg2' and K+ (36). Inthepresenceofpotassium,
vanadate blocked the conformnational change of
(Na+, K+)ATPase (E2K -* E1K) which normally
follows the hydrolysis of the phosphoenzyme (37).
Itwassuggestedthatinhibitionof(Na+, K+)ATPase
activity was duetotheformationofastableternary
complex of enzyme, vanadate, magnesium, and
potassium (37). It was proposed that vanadate's
ability to act as a phosphate transition-state analog
(Fig. 2) was responsible for the high affinity of
vanadate for the phosphatase site on the enzyme.
The affinity ofphosphate and arsenate for this site
was approximately 105_106 times lower than that of
vanadate. Arsenate alsoinhibited dogkidney (Na ,
K+)ATPase by binding to the weak ATP site (36).
E + ADP + H2V7 ¢. E' * ADP* H2VO4
E = myosin ATPase
K+ *E2 *ATP + H2VO + Mg2e+ T
(1)
(2)
K+ *E2 * ATP * H2VO7F Mg2+
Vanadate markedly enhanced adenylate cyclase
activity in ventricular muscle from rat, rabbit,
235guinea pig and cat (38) and in rat fat cells (39), and
inhibited stimulation ofsodiumand watertransport
by cyclic AMP in frog skin (40). Since vanadate has
no effect on purified cyclic AMP phosphodiesterase
the mechanism forthese effects was proposed to be
the inhibition of ATPase or GTPase by vanadate
(38-40). Molybdate was a reversible activator of
adenylate cyclase fromrat liver plasmamembranes,
rat erythrocyte ghosts and rat cardiac, kidney, and
brain homogenates (41). The molybdate did not
activate the soluble rat testicular adenylate cyclase,
and therefore it was suggested that molybdate
indirectly activated the enzyme by inhibiting GTPase
activity. Chromate and tungstate inhibited rat liver
adenylate cyclase activity at concentrations where
molybdate markedly stimulated activity (41).
Arsenate prevented the alkaline phosphatase-
mediated inactivation of glucocorticoid binding ca-
pacity of unbound soluble receptors from L929
mouse fibroblasts (42). Molybdate inhibited the
alkaline phosphatase activity ofrat thymus pellets
and prevented the reduction in glucocorticoid bind-
ingcapacity ofunoccupied ratliverreceptors caused
bythymus pellets (43). Molybdate also inhibited the
inactivation of unbound soluble glucocorticoid re-
ceptor from L929 mouse fibroblasts (43), whereas
tungstate had no effect on receptor inactivation
(44). The transformation of glucocorticoid bound
receptor from mouse fibroblasts into the form
which binds DNA was blocked by molybdate and
tungstate (44). Chick oviduct cytosol phosphatase
activity was inhibited by arsenate, chromate, mo-
lybdate, tungstate, and vanadate (45). Molybdate,
tungstate, and vanadate (but not chromate or
arsenate) were potent inhibitors ofthe activation of
progesterone receptor from chick oviduct to the
state which binds DNA (45). It was proposed that
molybdate interacted directly with the steroid
receptors, possibly by forming a phosphate com-
plex with the phosphorylated receptor and thereby
preventing its binding to DNA (44, 45).
Vanadate and arsenate markedly stimulated phos-
phate transfer to glucose by phosphoglucomutase,
whereas tungstate, molybdate, and niobate had no
effect (46). The half-maximal rate of phosphate
transferoccurred atpH 9.8and was shifted to 9.5in
the presence ofarsenate and to 7.7 in the presence
of vanadate. It was concluded that arsenate and
vanadate bind to phosphoglucomutase and lower
the pKa ofthe active site tyrosine hydroxyl group.
Arsenate, sulfate, molybdate, and tungstate were
competitive inhibitors of6-phosphogluconate dehy-
drogenase with respect to the substrate 6-phospho-
gluconate and were noncompetitive inhibitors with
respecttotheNADP+ cofactor(47). Permanganate,
periodate, perchlorate, and chromate irreversibly
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inactivated 6-phosphogluconate dehydrogenase, and
in the case of permanganate the inactivation was
ascribed to the oxidation ofcysteine to cysteic acid
(47). Fertate inactivated rabbit muscle phospho-
rylase b and prevented the binding of 5'-AMP to
the enzyme (48). The action offerrate was ascribed
to the oxidation of tyrosine residues at the phos-
phate binding site. Both arsenate and vanadate
replaced phosphate as a substrate in the glycer-
aldehyde-3-phosphate dehydrogenase reaction (49).
Vanadate and arsenate formed analogs of 1,3-
diphosphoglyceric acid whichwerelabileinaqueous
solution. The normal pathway offormation ofATP
from3-phosphoglyceraldehydeandphosphatethrough
the stable 1,3-diphosphoglycerate intermediate is
shown in Eq. (3), where GAPDH denotes glycer-
aldehyde-3-phosphate dehydrogenase. Substitution
of vanadate or arsenate for phosphate [Eq. (4)]
results in the formation of unstable acyl vanadate
or acyl arsenate intermediates which are quickly
hydrolyzed in aqueous solutions (49). Hydrolytic
decomposition ofthe acyl vanadate or acyl arsenate
drove the reaction to completion. Arsenate was
found to spontaneously form an ester-like product
withdihydroxyacetone (50). This arsenate analogof
dihydroxyacetone phosphate was recognized as a
substrate by glycerol 3-phosphate dehydrogenase.
Simple arsenate and vanadate trialkyl esters were
found to be very labile compared to phosphate
esters and appeared to undergo rapid exchange of
alcohol via a five-coordinate transition state (51).
Vanadium (V) in the form of the decavanadate
polyanion was apotentinhibitorofadenylatekinase
from rat liver mitochondria and rabbit skeletal
muscle (49). Sheep heart phosphofructokinase was
inhibited by vanadate in a manner similar to ATP
inhibition (52).
Molybdate, selenate, sulfate, sulfite, and arsenite
were competitive inhibitors of chicken liver mito-
chondrial pyruvate carboxylase with respect to
S-acetylCoA and decreased the rate ofinactivation
of the enzyme upon incubation at 2°C (53). Arse-
nate inhibition of pyruvate carboxylase was non-
competitive with respect to S-acetylCoA and it was
concluded that unlike the other oxyanions arsenate
acted at the nucleotide site rather than the S-
acetylCoA site (53).
In addition to acting as phosphate analogs, the
oxyanions have also been shown to act as sulfate
analogs and, therefore, interfere with sulfur me-
tabolism. The enzyme ATP-sulfurylase catalyzes
theformation ofadenosine-5'-phosphosulfate (APS)
from ATP and sulfate [Eqs. (5)-(8)], the first step in
sulfate reduction and in formation of the "active
sulfate" donor, adenosine-3'-phosphate-5'-phospho-
sulfate (PAPS). Sulfate is activated by formation of
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adenyl sulfate (APS), which acts as a sulfuryl donor
in subsequent enzymatic reactions such as sulfation
of polysaccharides [Eqs. (5)-(7)]. Selenate, molyb-
date, chromate, and tungstate form unstable AMP-
anhydrides which are hydrolyzed [Eq. (8)] to form
AMP and regenerate theoxyanions (54). Molybdate
was an irreversible inhibitor of Desulfn7ibrio ATP-
sulfurylase (11). Sulfite, chromate, molybdate, and
tungstate caused irreversible cleavage of ATP to
AMP by baker's yeast ATP-sulfurylase (54). Mo-
lybdate, chromate, tungstate, and selenate inhibited
the formation of APS by ATP-sulfurylase purified
from Nitrobacter agilis (55). Molybdate and sele-
nate inhibited ATP-sulfurylase activity by compet-
ing with sulfate for the active site on ATP-
sulfurylases purified from Pencillium chrysogenum
(56) and spinach leaves (57). Molybdate caused the
formation of AMP from ATP, however, no AMP
was formed with selenate as substrate for the
spinach leaf ATP-sulfurylase (57). Selenate was
found to act as a substrate for baker's yeast
ATP-sulfurylase and form adenoisine-5'-phospho-
selenate (APSe) which was stable enough to isolate
and characterize (54). The APSe was easily
hydrolyzed, however, resulting in the formation of
AMP and selenate. In contrast, APSe and AMP
were not detected when selenate was used as a
substrate for purified ATP-sulfurylases from As-
tragalus bisulcatus (a selenium-accumulator spe-
cies), Astragalus hamosus (a nonaccumulator spe-
cies), and spinach (57, 58). It was proposed that the
mechanism of inhibition by these anions [Eqs.
(5)-(8)] involved the formation of unstable adeno-
sine-5'-phosphoanion anhydrides which quickly
hydrolyzed toform AMP and the anion (54). Kinetic
studies on purified ATP-sulfurylases from Sac-
churmnyces cerevisiae(59),Penicilliumchrysogenum
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(56), and Furth mouse mastocytoma (60) suggested
asequentialmechanism forthe enzyme, where both
molybdate (or sulfate) and MgATP bind to the
enzyme before the products, pyrophosphate and
AMP-MoO4 (or APS), are released.
Molybdate was a reversible competitive inhibitor
of sulfate transport in the unicellular red alga,
Porphyridium aerugineum (61). Molybdate entered
these cells and inhibited the intracellular utilization
of the sulfate pool in the synthesis of capsular
polysaccharides. Sulfation levels of cell-associated
sulfated polysaccharide and the secreted extracellu-
lar sulfated polysaccharide were depressed by mo-
lybdate (61). Molybdate and selenate at concentra-
tions without effect on growth inhibited the
incorporation ofsulfate into cellular constituents of
Escherichia coli (62). Molybdate inhibited sulfate
reduction to sulfide by rumen microorganisms with-
out affecting sulfite reduction by these bacteria
(63). Molybdate was not toxic in a mutant of
Salmonella typhimurium lacking ATP-sulfuirylase
(64). Molybdate and selenate inhibited the synthe-
sis of APS in extracts from tobacco XD cells (65).
Molybdate derepressed ATP-sulfurylase in tobacco
cellsbyessentiallycausingsulfurstarvationthrough
inhibition ofsulfateuptake and sulfate activationby
ATP-sulfuruylase. Selenate derepression of ATP-
sulfurylase did not occur by a mechanism involving
sulfur starvation and it was proposed that
derepression was the result of the formation of a
seleno-analog which was an antagonist to some
product in the sulfate pathway (65).
Arsenitehasbeenshowntoinhibitthiol-containing
enzymes (66, 67), especially those containing two
sulfhydryl groups in close proximity, e.g., chicken
and rat liver citrate cleavage enzyme and the lipoic
acid-containing pyruvate oxidase system (68). Other
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enzymes, such as aldehyde dehydrogenases (69)
and glutamine synthetase (70), were inhibited by
arsenite only in the presence of exogenous mercap-
tan. Enzyme activity could be restored by addition
of dithiols and in some cases by addition of excess
monothiols such as glutathione and cysteine. An
antidote used for arsenic poisoning, 2,3-dimercap-
topropanol, British antilewisite (BAL), has been
shown to react with arsenite through the two
sulfhydryl groups [Eqs. (9) and (10)], forming a
stable five-membered ring structure (71). The level
ofmucosal glutathione was immediately depressed
after oral administration ofarsenic trioxide (As203)
to rats (72). This effect was attributed to the
binding of arsenite to glutathione. Glutathione
levels in mucosal cells subsequently rose to twice
the normal concentration in response to its deple-
tion by arsenic (72). Arsenite inhibited the activi-
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ties ofrabbit liver aldehyde oxidase, milk xanthine
oxidase and chicken liver xanthine dehydrogenase
by binding at the molybdenum active sites in these
molybdoenzymes (73). Arsenite was found to
reversibly inhibit acetylcholinesterase by a mecha-
nism not involving disulfide or sulfhydryl functions
although kinetic data suggested a covalent interac-
tion between the arsenite and enzyme (74).
Selenites have been shown to react with sulfhy-
dryl groups in cysteine, glutathione, dihydrolipoic
acid, 2-mercaptoethanol, coenzyme A and in pro-
teins(75-77). Selenite, acting as anoxidant, inhibited
enzymeinteractionsrequiring afreesulfydrylgroup.
Conversion of thiols to disulfides by selenite was
shown to involve a selenotrisulfide intermediate
[Eqs. (11) and (12)], which could be isolated from
the reaction mixture. A selenotrisulfide derivative
of glutathione was enzymatically reduced to the
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persulfide analog by glutathione reductase (78).
The selenopersulfide produced [Eq. (12)] decom-
posedtoglutathione andselenium(O). Selenitereacted
with reduced pancreatic ribonuclease A forming a
slightly unfolded structure containing intramolecu-
lar selenotrisulfide linkages which was devoid of
activity (79). Selenite was able to release methyl-
mercury bound to sulfhydryl groups in blood pro-
teins such as albumin in the presence of red blood
cells, and liver, kidney and brainhomogenates from
rats and mice (80). Selenite was effective in remov-
ingboundmethylmercuryfromhumanblood, whereas
selenate was ineffective. In vivo administration of
selenite tomicepreviouslyexposedtomethylmercury
resulted in the release offree methylmercury from
blood, liver and kidney tissue, but not from brain
tissue (80).
Inthe presence ofglutathione selenite stimulated
the swelling of liver mitochondria isolated from
selenium-deficient rats (81). Selenate, arsenite,
arsenate, sulfite, thiosulfate, molybdate, tellurate,
and vanadate had little or no effect on mitochon-
drial swelling in this system whereas tellurite was
slightly active. The swelling effect ofselenium was
attributed to the ability of selenite to catalyze the
reduction of cytochrome c by glutathione (82).
Selenocysteine also catalyzed glutathione reduction
of cytochrome c, selenate had only a slight effect
and selenomethionine was ineffective. It was pro-
posed that the mechanism for selenite catalysis of
cytochrome c reduction by glutathione involved the
formation of a selenopersulfide intermediate (82).
In rat erythrocytes, selenite stimulated reduction
ofmethemoglobin in the presence ofglutathione at
concentrations which had no effect on NADH-
August 1981
meth.emoglobin reductase activity (83). Several
proteins involved in electron transport processes,
e.g., formate dehydrogenase, glycine reductase,
and glutathione peroxidase, have been identified as
selenoproteins (84).
In summary, oxyanions of vanadium, chromium,
molybdenum, tungsten, arsenic, and selenium
inhibited the activity of enzymes involved in phos-
phate and sulfate metabolism. Selenite and arsenite
inhibited processesrequiringfreesulfhydryl groups.
Selenite affected electron transport reactions. Cel-
lularregulatory processes may be affected by these
oxyanions through their disturbance of oxidative
phosphorylation, inhibitionofoxidasesandATPases,
and interference with steroid effects on levels of
cAMP, e.g., activation of adeynlate cyclase activi-
ty, and interference with steroid-receptor-DNA
interactions.
Metabolism
The oxyanions, except phosphate, are redox
active and have other forms in different oxidation
states which are stable in aqueous solution (1).
Metabolic processes. may be able to convert the
high oxidation state metals in oxyanions to stable
complexes with the metal in a lower oxidation
state.
Liver and kidneys from rats treated with vana-
date exhibited an electron paramagnetic resonance
(EPR) signal characteristic of vanadium (IV) indi-
cating these tissues were able to reduce vanadate
by one electron (85). Lungs contained only small
amounts of vanadium (IV) and heart tissue had no
detectable V (IV). Toxic levels of vanadate had no
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effect on the activities of two molybdenum en-
zymes, sulfite oxidase and xanthine oxidase. It was
suggested thatthe toxicity ofvanadium wasrelated
to the one electron reduction of V (V) and subse-
quent binding of the V (IV) to protein. Intact red
blood cells converted vanadate to a form which
bound to hemoglobin (5). Red cell ghosts and pure
hemoglobin were inactive in vanadate conversion.
The vanadium associated with hemoglobin had the
EPR spectrum characteristic ofvanadyl ionindicat-
ing that reduction of vanadate to vanadium (IV)
had occurred (86). In contrast to vanadate which
markedly inhibited (Na+, K+) ATPase, vanadium
(IV) was a much less effective inhibitor (86). Rapid
oxidation of NADH occurred in the presence of
vanadate and purified calf cardiac cell membranes
containing (Na+, K+) ATPase (87). This effect was
attributed to the presence of a heat labile NADH-
vanadate reductase activity in cardiac membranes.
Catechol, which reduced vanadium (V) to vanadium
(IV) and formed a complex with vanadium (IV)
reversed the vanadium (V) inhibition ofreactivated
sea urchin sperm motility, dynein ATPase and
(Na+, K+) ATPase (30). Norepinephrine reversed
vanadateinhibitionofdogkidney(Na+, K+)ATPase
by reduction of vanadium (V) and complexation of
the vanadium (IV) formed (88).
Human breast, liver, and thyroid tissues which
had been treated with dichromate or with the Cr
(VI) containing tissue preservative, Zenker's solu-
tion, showed an EPR signal characteristic of chro-
mium (III) (89). The intracellular chromium in
chromate treated tumor cells was found as chro-
mium (III) complexed with organelles (nuclei,
mitochondria and microsomes), soluble proteins
and small molecules (7-9). The intracellular chro-
mium (III) complexes, even in the form of low
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molecular weight complexes, were retained in the
cell indicating the cell membrane was relatively
impermeable to trivalent chromium. Only chro-
mium (III) was detected in BHK21 hamster
fibroblasts that had been treated with dichromate
(90).
Treatment of red blood cells with chromate
resulted in uptake of chromium and recovery of
chromium bound to the globin (nonheme) portion of
hemoglobin (6). In contrast to the inactivity of
purified hemoglobin in vanadate reduction (5) he-
moglobin was capable of reducing chromate and
binding chromium (III) (6, 91). With both red blood
cell-labeled hemoglobin and isolated hemoglobin a,
I, and y polypeptides, chromium (III) was found
preferentially to bind to the ,B chains (91). Chro-
mium (III) was not taken up by red blood cells
suggesting that the erythrocyte membrane was
also impermeable to Cr (III) complexes (6). Chro-
mate inhibited glutathione reductase activity of
erythrocytes, whereas chromium (III) had no effect
(92). Chromatehad noeffect onacetylcholinesterase,
and glyoxalase activities, and on activities of en-
zymes of the glycolytic and pentose-phosphate
pathways of erythrocytes (92).
Chromium (VI) inhibited benzpyrene (BP)
hydroxylase activity in rat lung homogenates (93).
Chromium (III), arsenite and selenite had no effect
on BP hydroxylase in vitro (93). Potassium chro-
mate inhibited hydroxylation ofBP by mouse liver
homogenates, however, the same study showed
that potassium dichromate enhanced BP hydro-
xylation at low concentrations and inhibited at high
concentrations (94). Chromium (III) inhibited BP
hydroxylase activity in rat liver microsomes (95).
The microsomal fraction of rat liver cells was
found to be capable of metabolizing chromate to
Environmental Health Perspectives
(11)chromium (III) using NADPH or NADH as cofac-
tor (96, 97). The enzymes composing the electron-
transport cytochrome P-450 system were shown
(98) to be involved in the microsomal reduction of
chromate. The NADPH-dependent chromate re-
ductase activity of microsomes was inhibited by
carbon monoxide and metyrapone, known inhibi-
tors of cytochrome P-450 activity (98). The ability
of cytochrome P-450 to function as a NADH- or
NADPH-dependent reductase, rather than a
monooxygenase, has been well documented for a
number of organic substrates (99). Some of the
chromium (III) produced by microsomal reduction
remained bound to microsomal protein and the
majority was complexed to the NAD+ or NADP+
cofactor (97). Since chromate is not a strong oxidiz-
ing agent at physiological pH, no interaction be-
tween the negatively charged chromate ion and the
negatively charged DNA polymer was observed in
aqueous pH 7.4 solutions in vitro (97, 100). How-
ever, the presence of a microsomal metabolizing
system capable of reducing chromate to chromium
(III) caused significant amounts of chromium to
bind to DNA (97).
These results lead to an uptake-reduction model
(Fig. 3) to explain the carcinogenicity ofchromium
(VI) (97). Chromium in the formn of chromate
penetrates the cell membrane using the sulfate
transport system whereas chromium (III) does not
cross cell membranes and is effectively excluded
from the cell. Cellular metabolizing systems, in-
cludingthemicrosomalelectron-transport cytochrome
P-450 system, reduce chromate to chromium (III).
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Themetabolically produced chromium (III) bindsto
nucleic acids, proteins and small molecules such as
nucleotides. The chromium (III) bound to DNA
and/or protein induces damage to the DNA that
eventually leads to a mutation and hence cancer.
Possible cocarcinogenic effects ofchromium may be
enzyme inhibition by bound chromium and/or by
chromium-small molecule complexes. Extracellular
chromium may interfere with normal receptor ac-
tivities at the membrane and thereby disrupt
cellular regulatory processes.
Chromium (III)-nucleotide complexes have been
synthesized which have Cr3+ bound to phosphate
groups(101, 102). TheseCr3+-nucleotideshavebeen
used as inhibitors and/or substrates ofa number of
phosphoryl transfer enzymes, e.g., acetate, pyr-
uvate and 3-phosphoglycerate kinases, hexokinase,
glycerokinase, creatine kinase, and phosphofructo-
kinase (103). CrADP was shown to compete with
MgATP, the normal substrate for hexokinase, for
binding at the active site of the enzyme, whereas,
P--y-CrATP was shown to be a substrate for
hexokinase (104).
After oral administration of chromium (III) to
rats the chromium specifically was bound to the
serumproteintransferrin(105). TheaffinityofCr3+
for transferrin was close to that ofiron (III). Rats
injected intravenously with vanadate retained va-
nadium in the plasma as a vanadium-transferrin
complex(106). BothCr3+ andVO2+ havebeenshown
to bind to the Fe3" sites of transferrin (107).
Transferrin has been shown to bind to receptors on
reticulocytes andbecomeinternalizedbyendocytosis
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FIGURE 3. Uptake reduction model for the carcinogenicity of chromium (VI).
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.k Jr(108). The affinity ofCr3+-saturated transferrin for
reticulocytes was about halfthat ofFe3+ saturated
transferrin (109). The reticulocytes do not take up
Cr3+ from Cr3+-transferrin bound at the receptor
site (109). It has been suggested that transferrin
mayfunction as acarrierformetals otherthaniron,
i.e., Co2+, Cr3+, Mn2+, Cu2+, Zn2+, Mo4+, and
V4+ (107).
Rumen fluid that had been incubated with mo-
lybdate exhibited an EPR signal characteristic of
Mo (V) (11). Microorganisms such as the yeast
Pichia guillermondii and the bacterium Micrococ-
cus reduced molybdenumtrioxide andmolybdate to
molybdenum blue which is characteristic of penta-
valent molybdenum complexes (110). Mo (V) EPR
signals have been detected in bacteria, plant and
animal tissues which contain molybdenum enzymes
such as xanthine oxidase, sulfite oxidase and for-
mate dehydrogenase (111). Rats were capable of
incorporating molybdenum into liver sulfite oxidase
and xanthine oxidase when injected with molyb-
date, however, molybdate was not able to reconsti-
tutethe apoenzymes invitro (112). Pentavalent and
hexavalentmolybdenumwererapidlyexcreted from
the rat after IV injection; however, at high doses
(4.6 mg Mo/kg body weight) pentavalent molybde-
num was retained to a greater extent than the
hexavalent forminblood, liverandjejunoileocoecum
(113). It was proposed the biliary excretion of
hexavalent molybdenum involved the secretory
activity ofhepatic cells and the liver cells oxidized
molybdenum (V) to molybdenum (VI) which was
then excreted in bile (113). When cupric molybdate
was added to serum, the molybdate remained in
solution as the free anion (11). Molybdenum was
associated with red cells and plasma in the blood of
sheep after oral administration ofmolybdate (114).
All ofthe molybdenum in blood was dialysable and
it was suggested that its form in both plasma and
red blood cells was molybdate (114). Incubation of
humanerythrocytes withmolybdenum (V) complexes
resulted in labeling of the phosphorylated mem-
brane protein spectrin (115). Incubation of human
and rat serum with molybdate resulted in molybde-
num bound to a2-macroglobulins (116).
Mouse liver extracts enzymatically converted
selenite into dimethylselenide (117). Glutathione
and S-adenosyl-L-methionine were required for the
liver microsomal reduction and methylation ofsele-
nite and arsenite was an inhibitor of the reaction
(117). Purifiedyeast glutathionereductase catalyzed
the reduction of selenite to hydrogen selenide
under anaerobic conditions inthe presence ofgluta-
thione and NADPH (118). It was proposed that the
mechanism of selenite reduction involved the for-
mation of selenodiglutathione from nonenzymatic
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reaction of glutathione and selenite which was
reduced stepwise by glutathione reductase to glu-
tathione selenopersulfide and then to hydrogen
selenide (118). Dimethylselenide was exhaled by
rats fed selenate or selenite (119). Trimethylsele-
nonium ion (CH3)3Se', was the major urinary me-
tabolite in rats injected with selenite, selenate,
selenocystine, selenomethionine and methylseleno-
cysteine, orfed seleniferous wheat (120). Hydrogen
selenide was released upon acidification of liver
homogenates from selenite-treated rats and was
mainly associated with the mitochondrial and
endoplasmic reticulum fractions (121, 122). In addi-
tion to selenide, selenite and higher oxidation
states of selenium including organic derivatives
were found in the liver of rats treated orally with
selenite (122). Selenium-bound proteins were iso-
lated from the plasma ofrats injected with selenite
(123). Incubation of selenite with plasma or whole
blood in vitro did not produce the selenium-bound
plasma proteins. It was suggested that metabolism
of selenite was necessary for incorporation of sele-
nium into these proteins (123). The activity of
glutathione peroxidase, aseleno-enzyme, wasraised
in mouse neuroblastoma cells upon exposure to
selenite (124). Selenate produced no increase in
enzyme activity and it was suggested that these
cells had no mechanism capable ofreducing selenate
to selenite (124). Selenite was rapidly taken up by
mouselungfibroblastsandincorporatedinglutathione
peroxidase whereas, selenomethionine was slowly
taken up by the cells and its selenium became
associated with glutathione peroxidase only after a
long lag period (125). Selenocysteine has been
identified as the form of selenium in rat liver
glutathione peroxidase (126).
Selenium was incorporated into prolyl-tRNA of
Clostridium sticklandii incubated with selenite or
selenocysteine by a process highly specific for
seleniumnotby selenium simply actingas analog of
sulfur (127). Rumen microorganisms were capible
of reducing selenate to selenite and metabolizing
the selenite to a form (probably selenocysteine)
which was incorporated into microbial protein (128).
No synthesis of selenomethionine by rumen fluid
occurred from selenite or selenate and sulfate had
no effect on the incorporation of selenium into
protein. It was concluded that the metabolism of
inorganic selenium by rumen microorganisms was
different from that of inorganic sulfur (128). The
fungus Penicillium produced dimethylselenide, upon
incubation with selenite, selenate, or sodium sele-
nide (129). Dimethylselenide, dimethyldiselenide,
and dimethylselenone or methyl methylselenite was
formed by soil and sewage sludge microorganisms
treated with selenite or elemental selenium (130).
Environmental Health PerspectivesInjection of arsenate intravenously in dogs re-
sulted in excretion of some arsenite in the urine
(131). Renal reduction of arsenate occurred
intracellularly. Very little reduction of arsenite
occurred upon incubation with blood or urine in
vitro. Renal tubular cells were permeable to both
arsenite and arsenate and phosphate was an inhibi-
toroftransport ofboth ions (131). Livertissue from
cows fed arsenate showed onlypentavalent arsenic,
indicating no reduced form ofarsenic was retained
in the tissues (132). The same results were found in.
a similar study with arsenite (133). More than 50%
ofarsenic excreted intheurineofdogs and cowsfed
arsenate or arsenite was methanearsonate (134).
Livers of rats fed arsenate showed only pentava-
lent arsenic (135). Rats were unique amonganimals
tested in their ability to retain large quantities of
arsenic in the blood when fed either pentavalent or
trivalent arsenic (132). The arsenic was found to be
bound mainly to hemoglobin in the blood (136).
Cacodylic acid was not converted into inorganic
arsenic by rats administered the compound by
intravenous injection, intratracheal instillation or
oral gavage (137). The major site of retention of
cacodylic acid was in the red blood cells (137).
Arsenic in humanurine was predominantly in the
form of cacodylic acid, As(CH3)202H, with lesser
amounts of arsenate and small amounts of metha-
nearsonic acid and arsenite present (138). Copper
smelter workers exposed mainly to airborne arse-
nic (III) excreted mainly dimethylarsinic acid (65%)
and methylarsonic acid (20%), along with small
amounts ofarsenite (9%) and arsenate (6%) in their
urine (139). Ingestion of wine containing arsenic
(III) by humans resulted in urinary excretion of
dimethylarsinicacid(50%), methylarsonic acid(14%),
arsenite (8%), and arsenate (8%) (140). Arsenate
was rapidly excreted in the urine of humans after
ingestion of arsenate in well water; slower excre-
tion of small amounts of arsenite and substantial
amounts ofdimethylarsinic acid and methylarsonic
acid was observed (140).
The microorganisms Scopuloriopsis brevicaulis,
Candida humicola, and Gliocladium roseum pro-
duced volatile trimethylarsine whenincubated with
arsenic trioxide (As203), methylarsonic acid or
dimethylarsinic acid (141). The methyl donor used
for the biological methylation of arsenic by these
microorganisms was S-adenosylmethionine (141).
Methylcobalamin served as the methyl donor in the
methylationofarseniteorarsenatetodimethylarsine
by cell extract ofMethanobacillus strain M. 0. H.
(142). Bacteria cultured from sea water reduced
arsenate to arsenite (143). The marine alga,
Tetraselmis chuii, and Daphnia magna incorpo-
rated arsenic from arsenate into the lipid fraction
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(144). The arsenic compound was hydrolyzed by
phospholipases and was tentatively identified as an
arsenic-containing choline. An arsenylated low mo-
lecularweight substance which cochromatographed
with phosphatidylethanolamine was isolated from
arsenate-treated rat liver mitochondria (145).
A number of metabolic processes have been
identified to be involved in biological conversions of
oxyanions into different forms, e.g., NAD(P)H-
dependent redox processes, reactions involving
active sulfhydryl groups, and methyltransferase
reactions.
Mutagenicity
Chromate has been detected as a mutagen in the
Salmonella typhimurium Ames assay whereas
chromium (III) was not mutagenic in this system
(146). Addition ofa complete microsomal activation
system decreased the mutagenicity of chromate
(147). Since amicrosomal systemhasbeen shownto
convert chromate to chromium (III) (96), the de-
crease in mutagenicity can be explained by the
microsomal conversion ofthe mutagenic chromium
(VI) to the nonmutagenic chromium (III). Arsenite
and arsenate were not mutagenic in the Ames
assay (146). There are confficting reports on the
mutagenicity ofselenite in the Ames assay. In one
case both selenite and selenate were found to be
mutagenic (148) whereas the other report found
mutagenicity with selenate but not with selenite
(146). The Bacillus subtilis rec-assay showed that
both arsenite and arsenate were mutagenic al-
though arsenite was a stronger mutagen (149). The
rec-assay showed that chromate was mutagenic but
not chromium (III); permanganate was not muta-
genic but manganese (II) was positive; molybdate
was positive but pentachloromolybdenum (V) was
negative; both selenate and selenite were negative
(150) at low concentrations but were positive at
higher concentrations (144); and both vanadyl chlo-
ride and vanadate were positive (150). Arsenite,
dichromate and molybdate were mutagenic in E.
coli strings which were recA+ but not in a strain
carrying reck (148). Chromate was mutagenic in
E. coli WP2 wild strain and in exrAk and uvrA-
strains, whereas chromium (III), and soluble salts
of molybdenum and tungsten were not mutagenic
(151). Fluctuation tests which use E. coli WP2
Trp+ reversion detected chromate as a mutagen
(152). Arsenite decreased the survival of UV-
irradiated wild-type E. coli WP2 but had no effect
on the survival of a recA mutant, suggesting
arsenite inhibited recA-dependent DNA repair (153).
Arsenite was not mutagenic to E. coli WP2 at low
243concentrations (154). Methylated forns of arsenic
were not mutagenic in bacterial assays (66).
Chromate and arsenite enhanced the transforma-
tion of Syrian hamster embryo cells by simian
adenovirus SA7(155). Chromatetransforned BHK21
cellsinvtitro(156);chromateandarsenatetransformed
Syrian hamster embryo cells, however, tungsten
did not cause tranformation (157). Chromosomal
aberrations were induced in cultured FM3A mouse
mammary carcinoma cells by chromium (VI) and
permanganate, but not by chromium (III) and only
at a low level by manganese (II) (158). Chromate,
but not chromium (III), induced chromosomal aber-
rations and sister chromatid exchanges (SCE) in
human fibroblasts (159) and in Chinese hamster
ovary cells (160). The number of chromosomal
aberrations in Syrian hamster embryo cells caused
by chromium (VI) was diminished upon addition of
the reducing agent sulfite (161). Arsenate induced
dose-dependent SCE's and chromosomal aberra-
tions in normal human lymphocytes (162). Arsenite
and acetylarsan caused chromosomal aberrations in
human leukocyte cultures, however, no chromo-
somal aberrations were induced by arsenate, sele-
nite, selenate or metavanadate (163). Arsenite also
induced chromosomal aberrations in human diploid
fibroblasts (162). In another study, selenium (VI)
compounds induced chromosomal aberrations in
cultured human leukocytes whereas selenium (IV)
compounds were inactive (164). Selenite did not
cause SCE's in purified human lymphocyte cultures
or xeroderma pigmentosum cells, however, addi-
tion ofred blood celllysate with selenite resulted in
induction ofSCE in both cell types (165). Induction
of chromosomal aberrations and DNA-repair syn-
thesis in human diploid fibroblasts by selenite was
enhancedbyadditionofamouseliverS-9microsomal
fraction and NADPH (166). Selenate induced only a
small amount ofDNA-repair synthesis which could
not be enhanced by addition of the S-9 fraction
(166).
Arsenic (V), selenium (IV), and chromium (VI)
did not affect the fidelity ofin vitro DNA synthesis
by a variety of DNA polymerases copying a poly[d
(A-T)] template (167, 168). Chromium (III) caused
a large increase in the error frequency of DNA
polymerases copying poly[d(A-T)] or poly[d(G-C)]
templates (167, 168). Cellular metabolism of the
oxyanions which initially enter cells is obviously
important in determining their mutagenic poten-
tial.
Divalent Ions
Mostothertoxic and/ormutagenic metals existas
divalent metal ion complexes in neutral aqueous
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solution (1), e.g., Be2+, Mn2+, Co2+, Ni2+, Cu22+
Zn2+,Cd2 I,Pt +, Hg2+,andPb2+,althoughhigher
or lower oxidation states are possible depending on
the particular metal and coordinated ligands. The
ionic radii ofthe first row divalent transition metal
ions lie between those ofMg2+ and Ca2` (1). Other
divalent metal ions can replace or mimic ions such
as magnesium and calcium, which are extremely
important in biological systems, and iron, zinc,
copper, cobalt, and manganese, which are essential
components-ofLmany enzymes or coenzymes.
E. colicellswere found tobe highlypermeable to
manganese ion which was a potent mutagen in the
bacteria (169, 170). Magnesium competed with
manganese uptake by the cells and reduced the
number ofmutations (170). Manganese was able to
substitute for magnesium during in vitro DNA
synthesisbyavianmyeloblastosis DNApolymerase,
however, Mn2+ increased the incorporation of
noncomplementary nucleotides into the complemen-
tar strand (171). Subsequently it was found that
Be ,Cd2+ NO+,andPb inaddition
to Mn2+ decreased the fidelity of DNA synthesis
in vitro (168). In the case of Be2+ infidelity was
ascribed to the interaction of Be2+ with the DNA
polymerase enzyme (171). Manganese was also
found to be mutagenic in the B. subtillis "rec-
assay" as were cadmium and methyl mercury,
however, in this cellular assay system inorganic
salts ofBe2+, Co2+, Cu2+, Hgz Ni2+, and Pb2+
were inactive (149).
ReplacementofMg2+ byMn2+ relaxedthe speci-
ficityoftherestriction enzymes EcoRI and HindIII,
causing many more cleavages of DNA to occur
(173). Manganese enhanced the inhibition oftermi-
naldeoxynucleotidyltransferase(TdT)-catalyzedDNA
synthesis by ribonucleoside triphosphates (174).
Mn2+-dATP inhibited TdT by binding 10-100 times
stronger to the substrate binding site than other
Mn2+-deoxynucleotide triphosphates and therefore
blockingthereaction. DNAsynthesis byTdTinthe
presence of Mt+ was instantly inhibited upon the
additionofMn + (174).Mn2+ alteredthecomposition
of the RNA products fonned in vitro by Euglena
gracillus RNA polymerases I and II from zinc
sufficient cells and the single RNA polymerase
fromzincdeficientcells (174). TheabilityofMn2+ to
allowDNApolymerasetosynthesizeribosubstituted
DNA and to allow RNA polymerase to synthesize
deoxysubstituted RNA has been used for nucleo-
tide sequence determination (175). The specificity
ofcalfthymus ribonuclease H was decreased in the
presence of Mn2+ (176). All DNA-RNA hybrid
combinationswere cleavedwithMn2+ whereasonly
hybrids containing purine ribo strands were cleaved
with Mg2+ (176).
Environmental Health PerspectivesAddition ofMn2+ orFe3+ tomixtures ofratliver
microsomes and benzo[a]pyrene (BP) significantly
altered the formation ofthree diols of BP (177). It
was suggested that Mn2+ and Fe3+ could enhance
the carcinogenicity ofBP by altering the specificity
of microsomal metabolism (177). Cu2+, Zn2",
Pb2+, Ni2+, Fe2+, Fe3+, and Mg2+ inhibited the
metabolism of BP by rat liver microsomes; Mn2+
activated metabolism at low concentrations and
inhibited it at high concentrations (95). Another
study showed Co2 , Mg2+, and Al3+ enhanced the
hydroxylation of BP; and Zn2+, Cu2+, Pb2+,
Mn2+, Cd2 , and Ni2+ enhanced or inhibited hy-
droxylation depending upon the concentration of
the metal ion (94). An earlier study showed that
Be2 , Fe3+, and Mn2+ inhibited BP-hydroxylase
activity in rat lung homogenates; and Cu2+, Mg2+,
Fe2+, Zn2+, Ni2 , andCo2+ stimulatedtheenzyme
at low concentrations and inhibited activity at
high concentrations (93).
Mn2+ and Cu2+ enhancedunscheduled DNAsyn-
thesis induced by isoniazid and related hydrazines
in human fibroblasts whereas Fe3+ had no effect
(178). It was suggested that the DNA damage was
causedbyhydroxylradicalsproduced byreactionof
hydrogenperoxide with the metalions (178). Cu2+,
Co2+,Mn+, Fe2 , andZn2+ enhancedtheabilityof
thymine hydroperoxide to transform the DNA of
Haemophilus influenzae, and it was suggested that
the damaging agents were free radicals which
formed upon reaction of the metal ions with
hydroperoxides(178). Cu2+, Mn2+, Fe2+, andFe3+
enhanced induction of chromosomal aberrations in
Chinese hamster ovary cells by ascorbate (180).
Hydrogen peroxide, which produces reactive free
radicals, appeared to be the DNA-damaging agent
in these studies (180).
Pb2+,Cd2+,Cu2+,andMn2+ decreasedthefidelity
of DNA-directed RNA synthesis by E. coli RNA
polymerase, however, these ions stimulated chain
initiation at concentrations which inhibited total
RNA synthesis (181). It was suggested that these
ions promoted RNA initiation at sites on the DNA
template not normally recognized as initiation sites
(181).
Mn2+ replacedMg2+ atahighaffinitybindingsite
on tubulin and promoted tubuZn bolymerization to
microtubules (182). Co2+ and Zn +, but not CO+,
also bound to the same site, however, tubulin
sheetsratherthan the microtubules formed intheir
presence indicating that Co2+ and Zn2+ induced a
differentconformationoftubulinthanMn2+ orMg2+
(182). ReplacementofCa2+ byMn2+ intheextracel-
lularmediaresultedinadecreaseinthetryptophan
hydroxylase activity of slices of rat brain stem
(183). It wasconcluded thatCa2+ regulated trypto-
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phanhydroxylaseactivityviaMn2+ -sensitive Ca2+
channels in the nerve membrane (183). Co2+ was a
potent inhibitor ofCa2+ translocation mediated by
the ionophore A23187 into a hydrophobic domain
(184). Co2' aggregated at synaptic sites and on or
near microtubules along the neuronal membranes
afterinjection ofCo2+ intotheneurons ofthe locust
Schistocerca americana gregaria (185). Since
calmodulin has been localized at these sites it was
suggested that Co2+ bound to calcium-binding pro-
teins in or near the membranes and microtubules
(185).Co2+ andMn2+ blockedthecalciumchannelsin
nerve cell bodies of Tritonia diomedia (186) and in
squid axons (187) in a competitive manner. Mn2 ,
Co2+, and Ni2+ also decreased the Na+ currents in
squid axons but had noeffect on K+ channels (187).
Mg2+, Ca2+, Sr2+, Mn2+ and Ni2+ decreased the
current induced by acetylcholine at the neuromus-
cular junction of the frog cutaneous pectoris mus-
cle, however, Ni2+ and Sr2' markedly lengthened
the current decay rate whereas Mg2+, Ca +, and
Mn2' had little effect on the rate (188).
Substitution of zinc in zinc-metalloenzymes by
other metals resulted in fully active enzymes or
enzymes with altered activities. Substitution of
Ni2+forZn2+ intheregulatorysubunitsofaspartate
transcarbamoylase resulted in afullyactive enzyme
having allosteric properties of the native Zn-
enzyme (189). However, the native enzyme showed
a higher degree of cooperativity than the Ni2+
substituted enzyme possibly because the Ni2+ in-
duced a slightly different confonnation in the pro-
tein chains (189). Substitution of the zinc in car-
bonicanhydrasebyNi2+ resultedincompletelossof
esterase activity, however, the Cd2+-substituted
enzyme showed esterase activity above pH 9 (190).
Co +-substituted carbonic anhydrase retained full
esterase activity, however, substitution of Cd2+,
Mn2 , Ni2+, Fe +,Cr3+, orFe3 resultedinlossof
activity (191). Substitution ofall four atoms ofzinc
in horse liver alcohol dehydrogenase (192) or in E.
coli alkaline phosphatase (193) by Co2+ resulted in
decreased enzyme activity. Activities of various
metal-substituted alkaline phosphatases were cor-
related with the distance of the metal to a bound
water molecule (194). The Mn2+-alkaline phospha-
tase which was inactive had the longest Mn-H20
distance, 4.0 A; the Cu2+-enzyme with 3-5% the
native activity had a Cu2+-H2O distance of3.4 A;
and the Co2+-enzyme had a nearly nonnal distance
of 2.8 A and retained 10-20% the activity of the
native zinc enzyme (194). Cobalt-leucine amino-
peptidase had a higher specific activity with
L-leucine-p-nitroanilide substrate than the native
zinc enzyme (195). Substitution of Co2+, Mn2 , or
Cd2+ forZn2+ incarboxypeptidaseresultedinmark-
245edlydifferenteffectsonthepeptidaseandesteraseac-
tivities ofthe enzyme (196). The Co2+-, Mn2+_-, and
Cd2+-carboxypeptidase had essentially the same
binding affinity for peptide substrates as the native
zinc enzyme, however, the rate ofpeptide hydroly-
siswasmuchslowerbytheMn2+-andCd2+-enzymes
and substantially faster by the Co2'-enzyme. In
contrast, rates of ester hydrolysis were virtually
identical regardless of the metal, however, the
Zn2+- andCo2+-carboxypeptidase hadmuch higher
affinity for the ester substrates than the Mn2+- or
Cd2+-enzyme (196).
The tail baseplate of T-even bacteriophages was
shown to contain about 5 atoms ofZn2+ which were
necessary for activity of the phage particles (197).
Co2+, Cd2+, and Ni2+ were capable of restoring
activity to Zn-depleted phage particles whereas
little or no reconstitution of phage activity was
observed with Mn2+ C02+, Mg2+, Fe2+, Cu2+, or
Hg2+ (197). Co2+ and Ni2+ were able to substitute
invivo forZn2+ inthe tailbaseplate ofbacteriophage
T4D and permitted growthofactive phageparticles
on E. coli B (198).
Zn2+ inhibited glucagon-stimulated and fluoride-
stimulated adenylate cyclase activity in human
livermembranes(199). Zn2+ inhibitedacidphospha-
tase activity in the nuclear and particulate fractions
ofadult chicken liverhomogenates, whereas, Mg2+
slightly activated the enzyme activity (200). Zn2+
complexed with human rhinovirus type 1A coat
proteins and rendered them inactive as substrates
for proteases and prevented their use in the assem-
bly of the intact virus (201).
Zn2+ enhanced the dissociation of human a2132
oxy-or carbon monoxyhemoglobin tetramers to a3
dimers which contained one zinc bound per dimer
(202). It was suggested thatCSys 931, His 14313 and
His 1461 may coordinate Zn + and the resulting
charge repulsion may lead tothe observed dissocia-
tion (202). Zn2+ wasfound tobeconcentrated inthe
sulfhydryl-rich flagellar accessoryfibersofmamma-
lian and cephalopod sperm (203). Dexamethasone, a
synthetic glucocorticoid, stimulated the uptake of
Zn2+ in HeLa cells by inducing the synthesis of
metaliothionein, a crsteine-rich protein with high
affinityforZn2+, Cd +, Hg2+, Ag+, andCu+ (204).
Cd2+ inhibited solublerattesticularand livergluta-
thione peroxidase activity in vitro (205).
Cd2+ promotedincorporationofdelipidatedhuman
placental tissue factor into phospholipid vesicles
and thereby greatly enhanced recovery of the
coagulantactivityoftissuefactor(206). Cu +, Ni2+,
HgZ+, or Zn2+ decreased recovery of coagulant
activity, Ca2+, Mg2+, Sr2+ and Ba2+ had no
effect, and Mn2+ and Co2+ slightly enhanced
activity. It was suggested that the effectiveness of
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Cd2+ and Mn2+ was due to their known ability to
induce fusion of vesicles from lipids (206).
Mn2+ wasanoncompetitiveinhibitorofglutamine
synthetase activity in rat liver cytosol extracts
(207). Hg2+ and Cu2" strongly inhibited soya meal
urease activity, whereas, slight or no inhibition of
urease was observed in the presence of Ba2 ,
Cd2+ Co2+, Cr3+, Fe2+, Fe3+, Mn2+, Ni2+, Pb2 ,
Sn2+, Sr2+, or Zn2+ (208). Pb2+ stimulated phos-
phorylation of electroplax microsomal protein by
the (Mg2+ + Na+)-dependent protein kinase of
(Na+, K+)ATPase, thus inhibiting ATP hydrolysis
(209). Pb2+ replaced Na+ in stimulating the kinase
activity, whereas Fe2+, Ni2+, Cu2+, Zn2+, Sr2+,
Hg2+,Ca2+,Mn2 2,andCo2+ wereinactive. Methyl-
mercury and Hg2+ inhibited rabbit muscle sarco-
plasmic reticulum (Ca2+, Mg2+)ATPase and Ca2+-
transport by blockage ofessential sulfhydryl groups
(210). Hg2+ also competed with Ca2+ forthe Ca2+-
ionophoric site and inhibited Ca2+-transport.
Methylmercury, butnotHg2+, inhibitedthebinding
of acetylcholine to the acetylcholine receptor from
the electric organ of T. californica (210). It was
suggested that methylmercury reacted with sulf-
hydryl groups ofacetylcholine receptorwhich were
located in a hydrophobic environment inaccessible
to Hg + (210).
Pb + inhibited milk xanthine oxidase activity
(211). Pb2 ,Ag+ andHg2+ stronglyinhibitedrabbit
liverguanine aminohydrolase, asulfhydrylenzyme,
whereas Cd2 , Mn2+, Ca2+ Be2+ Zn2+ Ba2+
Cu2+, Sn2 , Mg2+, Fe2 , and Ni2+ exhibited no
inhibition ofguanase activity (211). Pb2+ disturbed
heme synthesis by inhibiting the cytoplasmic Zn-
dependent, sulfhydryl-rich enzyme, aminolevulinic
aciddehydratase, andthemitochondrialsulfihydrylen-
zyme, ferrochelatase (212). Cu2+, Hg2+, and Ag+
also inhibited aminolevulinic acid dehydratase (212).
Bacteria from marine sediments oxidized Mn (II)
to Mn (III) and this oxidation was shown to involve
type C cytochrome (213). Manganosuperoxide
dismutases found in bacteria, and mitochondria
were found to have manganese bound in the triva-
lent state (214). Transferrin was found to bind
manganese as Mn3+ (107).
Elementalmercury vaporreadily crossed red cell
membranes and was oxidized to divalent mercury
by catalase (215). Bacteria from marine sediments
methylated Hg2+ to methylmercury which was
accumulated by living organisms much more rapidly
and avidlythan Hg2+ (215). Organolead compounds
were methylated by microbial components of sedi-
ment, however, no stable methylated-derivative
was isolated with Pb2+ (216). Methylation of mer-
cury and lead involved methyl-B12 as the methyl
donor (216).
Environmental Health PerspectivesDivalent ions have diverse effects which may
contribute to their carcinogenicity or cocarcino-
genicity. They may substitute for essential ions
such as calcium, magnesium and zinc; they may
react with sulfhydryl groups ofenzymes; they may
alterenzyme andmembrane functions; theymaybe
metabolized to more toxic agents; they may be
incorporated into metalloenzymes; they may bind
to macromolecules or small molecules and alter
their normal activity in the cell; or they may
catalyze the formation oftoxic agents such as free
radicals.
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